Statistics from Altmetric.com
We read with great interest the publication in Gut by Himmelsbach et al1 in which they assessed whether the modulation of c-Raf by sorafenib affects hepatitis C virus (HCV) replication using the in vitro replicon system. The authors showed that sorafenib blocks HCV replication in vitro, by decreasing c-Raf phosphorylation and by affecting the post-translational processing of NS5A, which is required for the replication of the virus. We would like to report here a clinical observation that could suggest the clinical potential interest of kinase pathway inhibitors as a therapeutic option in chronic hepatitis C.
Erlotinib is a highly selective kinase inhibitor targeting epidermal growth factor receptor (EGFR), the signalling pathway of which includes the Ras/Raf/mitogen-activated protein kinase (MEK)/extracellular-related-signal kinase (ERK) pathway. Erlotinib has been approved in non-small cell lung …